{ "A Study of AC676 for Relapsed/Refractory B-Cell Malignancies", "This study is testing a new oral drug called AC676 for people with B-cell malignancies (cancers of certain white blood cells) that have returned or not responded to previous treatments. The main goals are to find a safe dose of AC676, understand its side effects, and see how well it works. AC676 works by targeting a specific protein called BTK, which is involved in the growth of these cancer cells. You may be able to join if you are at least 18 years old and have a confirmed diagnosis of certain types of relapsed/refractory B-cell lymphomas or leukemia. The study aims to enroll about 60 participants.", "design": "This is a Phase 1, first-in-human study where all participants will receive AC676. It is an open-label study, meaning both you and your doctors will know you are receiving the study drug.", "commitments": "AC676 will be taken by mouth in 28-day cycles. The study will monitor for side effects and laboratory changes for approximately 18 months.", "compensation": "Not stated in the trial record.", "follow_up": "The study will track side effects and laboratory changes for approximately 18 months after treatment begins.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.